Announced details
Third-line treatment for pancreatic cancer
Relationship involving receipt of approval to initiate a Phase 3 clinical trial of CBP501 developed by the Company
European Medicines Agency (EMA)
European Medicines Agency (EMA)
8 countries, approximately 50 sites (planned)
The impact on current-period results is expected to be minor, although depending on progress going forward, results may vary due to factors including an increase in development expenses.
The company does not address Contract Value / Offering price.
Clinical Trials Information System (CTIS)
| Item | Details |
|---|---|
| Names of Products / Services Covered | CBP501 (anticancer drug candidate compound and immune activator) |
| Counterparty | European Medicines Agency (EMA) |
| Counterparty overview | European Medicines Agency (EMA) |
| Relationship with the Company | Relationship involving receipt of approval to initiate a Phase 3 clinical trial of CBP501 developed by the Company |
| Launch date | Once the required procedures with the authorities in each country have been completed, site activation and subject enrollment are scheduled to begin sequentially. Trial completion is expected in the first half of 2029. |
| Applicable area | Third-line treatment for pancreatic cancer |
| Awarding / certifying body | European Medicines Agency (EMA) |
| Location | 8 countries, approximately 50 sites (planned) |
| Location scale | 8 countries, approximately 50 sites (planned); approximately 180 subjects in total across 2 groups |
| Impact on Business Performance | The impact on current-period results is expected to be minor, although depending on progress going forward, results may vary due to factors including an increase in development expenses. |
| Source | Clinical Trials Information System (CTIS) |
Items this document does not state (7)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.The Company received approval from the European Medicines Agency to initiate the Phase 3 clinical trial. It explained that the expected timing of trial completion could vary significantly depending on the trial start date, the pace of subject enrollment and the time required for the interim analysis.